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Tumor necrosis factor (TNF)-α is not just a proinﬂammatory cytokine. It has also been proposed to be an immunoregulatory
molecule that can alter thebalance of T regulatory cells. Anti-TNF-αtherapies have been provided clinical beneﬁt to many patients
and introduced for treating moderate to severe rheumatoid arthritis, Crohn’s disease, and other chronic inﬂammatory disorders.
However, their use also is accompanied by new or aggravated forms of autoimmunity, such as formation of autoantibodies,
including antinuclear antibodies (ANAs), antidouble-stranded DNA (dsDNA) antibodies, and anticardiolipin antibodies (ACL).
Systemic lupus erythematosus (SLE) is a disease with autoimmune disturbance and inﬂammatory damage. The role of TNF-α in
human SLE is controversial. Here we review the role of TNF-α in the pathophysiological processes of SLE and the likely eﬀects of
blocking TNF-α in treatment of SLE.
1.Introduction
Systemic lupus erythematosus (SLE) is a multifactorial
autoimmune disease characterized by breakdown of selftol-
erance, B cell hyperactivity, autoantibody production, aber-
rant formation of immune complexes (ICs), and inﬂamma-
tion of multiple organs [1]. As a pleiotropic cytokine that has
both immunoregulatory and proinﬂammatory eﬀects [2, 3],
Tumor necrosis factor (TNF)-α was reported to be increased
in SLE and correlated with disease activity [4], and it has
been proposed to contribute to the immunopathogenesis
of SLE [5]. Recently an open-label study showed that anti-
TNF therapy could suppress the local tissue destruction in
SLE, but at the same time, use of anti-TNF-α agent leads
to formation of autoantibodies, including autoantibodies to
double-stranded DNA (ds-DNA) and cardiolipin increased
[6]. As a consequent it was inferred that TNF blockade in
SLE could pose dangers. This paper will focus on the role of
TNF-α in the pathophysiological processes of SLE and the
likely eﬀects of blocking TNF-α in treatment of SLE.
2.Biology ofTNF-α
TNF-α is a pleiotropic cytokine produced by many cell
types, including macrophages, monocytes, lymphocytes,
keratinocytes, and ﬁbroblasts, in response to inﬂammation,
infection, injury, and other environmental challenges [7].
TNF-α is not only a potent proinﬂammatory cytokine but
also plays an important role in lymphocyte and leukocyte
activation and migration, fever, acute-phase response, cell
proliferation, diﬀerentiation, and apoptosis [8]. TNF-α
exerts its eﬀects through two distinct receptors: TNF recep-
tor 1 (TNFR1) and TNFR2 [9]. Binding of the inherently
trimeric TNF-α to TNFR1 and TNFR2 induces receptor
trimerizationandrecruitmentofseveralsignalingproteinsto
the cytoplasmic domains of the receptors. The ﬁrst protein
recruited to TNFR1 is TNFR associated death domain
(TRADD), which serves as a platform to recruit at least three
additional mediators, Fas-associated death domain (FADD),
receptor-interacting protein 1 (RIP-1), and TNF receptor-
associated factor 2 (TRAF-2) [9–13]. TNFR1 transduces
apoptoticandanti-inﬂammatorysignalsthroughtherecruit-
ment of FADD and subsequent recruitment and activation
of Caspase 8 then leading to the activation of caspase
cascade; the activation of Caspase 3 executes apoptosis
[13]. TNFR1 also mediates antiapoptotic and inﬂammatory
responses through the recruitment of TRAF-2 and RIP-1,
which are critical in the activation of nuclear factor-
kappa B (NF-κB), c-Jun NH2-terminal kinase (JNK), and
mitogen-activatedproteinkinase(MAPK)[14].Ontheother
hand, it is known that the occupancy of TNFR2 by TNF-
α leads to the recruitment of TRAF-1 and TRAF-2 [15].2 Journal of Biomedicine and Biotechnology
TRAF-2 is essential for the process of activation of NF-κB,
JNK, and MAPK, and mediates antiapoptotic and proin-
ﬂammatory eﬀects [16]. Therefore, TNFR2 is involved in
the antiapoptotic and inﬂammatory eﬀect of TNF-α whereas
TNFR1 is involved in both apoptotic/anti-inﬂammatory and
antiapoptotic/inﬂammatory signaling. The adapter proteins
such as TRADD, FADD, RIP-1, and TRAF-2 are pivotal
molecules in the apoptosis and inﬂammatory signal pathway
of TNF-α, they play as ‘bifurcations’ and are indispensable
[17].
TNF-α is both a proinﬂammatory cytokine and an
immunoregulatory cytokine. TNF-α has diﬀerential eﬀects
on B cells, T cells, and dendritic cells, as well as on the pro-
cess of programmed cell death. During the (auto)immune
response, TNF-α acts as a growth factor for B cells and may
promote dendritic cell (DC) maturation but leads to T cell
hyporesponsiveness and to the expression of antiapoptotic
molecules. The latter is very important in the immune
homeostasis: on one hand, TNF-α restrains autoreactive T
cells through the negative regulation of T cell receptor (TCR)
signal transduction and the induction of T cell apoptosis
in the peripheral blood [18]; on another hand, TNF-α
counteracts Fas-mediated apoptosis through the activation
of NF-κB and the induction of antiapoptotic molecules,
then decreases the stimulation to immune system caused by
apoptosis-derived nucleosome, and inhibits the production
of autoantibody [19]. From the aspect of inﬂammation, TNF
is induced by IC and promotes inﬂammation and secondary
tissue destruction; liberation of autoantigens during necrosis
could fuel autoimmunity [19].
By directing its two transmembrane receptors to deliver
signals of cellular proliferation, diﬀerentiation, or apoptosis,
TNF-α appears not only to orchestrate acute responses
to infection and immunological injury but also to act
as a balancing factor required for the re-establishment of
physiological homeostasis and immune regulation [20]. The
level, timing, and duration of TNF-α activity are of pivotal
regulatory signiﬁcance in immune physiology. Aberrations
in any of these factors result in perturbed phenotypes that
depend on a multitude of TNFR-mediated activities, be it
pro-inﬂammatory, immune activating, or even immunosup-
presive [20].
Within such pleiotropism of functions, blockade of
TNF-α in recent clinical trials of rheumatoid arthritis or
inﬂammatory bowel disease, although so far impressively
beneﬁcial for the majority of patients, has also led in
some cases to a signiﬁcant incidence of drug-induced anti-
dsDNA production and lupus and in manifestations of
neuroinﬂammatory disease [21–23]. TNF-α blocking could
relievetheinﬂammationinducedbyTNF-α,atthesametime
the immunoregulatory and antiapoptotic eﬀects of TNF-α
could also be blockade which may lead to autoimmunity
[24].
3. TNF-α Participatesin
SLEPathologic Changes
Disregulated TNF-α production, be it low or high, character-
izes many autoimmune diseases. Recent evidence supports
a dualistic, pro-inﬂammatory, and immune- or disease-
suppressive role for TNF-α in these conditions [20]. Because
of the complex genetics of SLE and the tight linkage of the
Tnf genewiththeMHClocus,thephysiologicalroleofTNF-
α and its adaptors in the pathogenesis of lupus has remained
uncertain [25].
3.1. Aberrant Immunoregulatory Eﬀects of TNF-α in SLE.
In the classic animal model of SLE, the (NZB×NZW)F1
mouse, initial studies demonstrated the beneﬁt of early
recombinant TNF-α (rTNF-α) administration, or TNF-α
boosting reagents, towards the onset of lupus nephritis but
not on B cell hyperactivity and autoantibody responses [26–
28].
Kontoyiannis and Kollias generated heterozygous
(NZB×B6, 129 Tnf
0)F1 mice, which have reduced TNF-α
production, by crossing NZB mice with TNF-α deﬁcient
mice [25]. (NZB×Tnf
0)F1 hemizygous mice developed
enhanced autoimmunity and severe renal disease similar to
the (NZB×NZW)F1 mice. Autoimmune responses were
associated with an early spontaneous increase in serum
levels of antinuclear autoantibodies and hyperproliferating
B cells which readily express anti-dsDNA speciﬁcities in
response to polyclonal and T helper stimuli. These ﬁndings
demonstrate a physiological role for TNF-α in suppressing
the emergence of autoreactive lymphocytes in the NZB
model and indicate that defective TNF-α function may be
causative of the autoimmune and pathological phenomena
in lupus [25]. Loss of physiological TNF-α production in
an autoimmunity prone background suﬃces to exacerbate
anti-nuclear autoimmunity and the development of disease
[25]. To that end TNF-α dysfunction may appear epistatic
to the dominance of MHC heterozygosity associated with
lupus autoimmunity [29, 30]. Genetic studies have indicated
that the hypoproducing Tnf
Z allele derived by the NZW
parent and the H-2d/z heterozygosity of the MHC locus are
dominant contributors to the susceptibility of this model to
autoimmunity [31, 32].
Kollias and Kontoyiannis also showed that TNF-α deﬁ-
cient mice in a mixed B6,129 genetic background (H-
2b/b) had a normal life span and appeared macroscopically
healthy, but they developed mild anti-nuclear autoimmunity
in the form of IgG2b and IgG3 anti-DNA antibodies [20].
In addition, 40% of female mice show mild IgG deposits
on their glomeruli and alterations in glomerular structure
resembling the initial stages of lupus nephritis (LN). In
contrast,clinicalsymptomsandterminalglomerulonephritis
do not develop [20]. The apparent lack of pathology in
the presence of ensuing autoimmunity can be explained
by the absence of the pro-inﬂammatory activities of TNF-
α.T N F - α has been indicated to play a dominant role in
mesangial macrophage activation, apoptosis of renal tubu-
lar epithelia, and antiglomerular antibody-induced kidney
destruction [33–36]. Recently, it was demonstrated that anti-
TNF administration suppressed experimental SLE induced
by the injection of human anti-DNA autoantibodies in mice
[37].
Apoptosis (programmed cell death (PCD)) plays an
important role in the homeostasis of the immune response.Journal of Biomedicine and Biotechnology 3
Peripheral blood lymphocytes (PBLs) from SLE patients
exhibit increased spontaneous and diminished activation-
induced apoptosis. Increased spontaneous apoptosis of PBLs
has been linked to chronic lymphopenia and comparted-
mentalized release of nuclear autoantigens in patients with
SLE [38]. The appearance of high numbers of autoreactive
lymphocytes in the peripheral blood of patients with SLE
might be a consequence of defective activation-induced
cell death (AICD) [39]. Kovacs B et al. [40] showed that
permeabilitized lupus T cells displayed signiﬁcantly lower
amounts of TNF-α, a functional Fas/Fas-ligand path and
adequate amounts of intracellular TNF-α were needed for
the CD3-mediated T cell death. Prolonged survival of
autoreactive T cells can lead to increased autoantibody
production. Defective activation-induced apoptosis in lupus
would worsen under TNF blockade.
The clinic reports about the levels of TNF-α in SLE
patients were controversial [41, 42]. In most studies, TNF-α
isfoundtobemarkedlyincreasedandappearstobebioactive
in the sera of patients with active SLE, and levels of TNF-
α have been shown to correlate with SLE disease activity
[4, 19]. Our previous study found that SLE patients had
elevated plasma levels of TNF-α as compared to controls,
however there was no correlation with disease activity [43].
G´ omez D et al. have showed that TNF-α levels and the
TNF/IL-10 ratio were higher in patients with inactive disease
comparedwithpatientswithveryactivediseaseandcontrols,
suggesting that TNF-α could be a protective factor in SLE
patients [42].
HLA-DR2- and DQwl-positive donors frequently exhibit
l o wp r o d u c t i o no fT N F - α whereas DR3- and DR4-positive
subjects show high levels of TNF-α production [44]. DR2,
DQwl-positive SLE patients show low levels of TNF-
α inducibility; this genotype is also associated with an
increased incidence of LN [44]. DR3-positive SLE patients,
on the other hand, are not predisposed to nephritis, and
these patients have high TNF-α production. DR4 haplotype
is associated with high TNF-α inducibility and is negatively
correlated with LN [44]. These data suggested that low TNF-
α production may be involved in the genetic predisposition
to LN, similar to the (NZB×NZW)F1 LN model system
[45] and may help explain the association between HLA-
DR2/DQwl and susceptibility to LN. However, a substantial
portion of SLE patients are DR3 associated; clearly these
patients do not have low TNF-α production, similar to
MRL-lpr/lpr and BXSB mice, which also show high levels
of TNF-α production [44]. This result suggests that SLE is
not a single condition but rather can be subdivided into at
least two subsets: one associated with DR2/DQwl increased
susceptibility to LN and low TNF-α production; the other
associated with DR3 and high TNF-α production associated
with lupus without nephritis [44].
Although TNF signaling adaptors are quite important in
thefunctionofTNF-α,therolestheyplayinthepathogenesis
of SLE are not clear by now. In our previous study, we
demonstrated that the expression of TRADD, FADD, RIP-
1, and TRAF-2 in PBMCs from SLE patients signiﬁcantly
decreased as compared with healthy control subjects [46].
These data pointed to that aberrant proapoptotic signals,
antiapoptotic signals, and proinﬂammatory signals of TNF-
α pathway may involve in the immunopathogenic injury in
SLE. These ﬁndings are consistent with the studies done
by K. Maas et al. in which they indicated that TRADD
and TRAF-2 in PBMCs of patients were downregulated in
SLE by gene assay analysis [47]. As TNFR1–TRADD–FADD
system leading to apoptotic signaling, the downregulation
of TRADD, FADD in PBMCs from patients with SLE may
promote an anti-apoptotic eﬀect. Defects in expression of
these genes may increase the likelihood that lymphocytes
avoid the normal processes used by the immune system to
eliminate unwanted lymphocytes or to down-regulate an
immuneresponse[48,49].Ifpatientscarrythisautoimmune
gene expression signature, signaling pathways essential for
the maintenance of tolerance may not function properly.
This may permit lymphocytes to escape tolerance and
adopt a prosurvival agenda that increases the likelihood
of autoimmune diseases. TNFR1–TRADD–RIP-1–TRAF-
2 system leads to the anti-apoptotic and inﬂammatory
signaling [7]. In our previous study, it was showed that
the more severity of the disease, the lower expression of
the three adaptor proteins of TRADD, RIP-1, and TRAF-
2, and it implied that there was less restraint of apoptotic
death [46]. The expression of Caspase 3 was also signiﬁcantly
upregulated in SLE patients. Self-antigen exposure has been
suggested to occur as a consequence of massive apoptotic
death, this death is accompanied by delayed removal of
apoptotic bodies due to defective phagocytosis of phagocytic
cells [50–52] .T h e s ee v e n t sg a v er i s et oal a r g en u m b e ro f
nucleosomes and intracellular proteins circulating in the SLE
sera[33,35],whichindicatethattherewasmassiveapoptotic
death. Development of autoantibodies and tissue damage are
predominant in most SLE patients [53]. The dysregulation
of programmed cell death is suggested to be involved in
the generation of autoantibodies. The low expression of
TRADD, RIP-1, and TRAF-2 in PBMCs might be one
of the etiopathogeneses leading to redundant apoptotic
death in SLE patients. Our study indicated that decreased
expressionofTRADD,RIP-1,andTRAF-2mRNAbyPBMCs
a n dr e s t r a i n e dT N F - α-induced anti-apoptosis, as well as
advanced lymphocyte apoptosis, may play a role in the
pathogenesisforthelossofimmunetoleranceandredundant
apoptotic cell death, leading to massive production of
autoantibodies in SLE patients [46]. These abnormalities
may participate in the immunopathogenic injury mediated
by the aberrant TNF-α signaling pathway in SLE.
3.2. Inﬂammatory Eﬀects of TNF-α in the Pathogenesis of SLE.
TNF-α is the most important proinﬂammatory cytokine and
a harbinger of tissue destruction, and it is at the top of
a pro-inﬂammatory “cascade” leading to tissue damage. In
contrast to the complex role of TNF-α in apoptosis and
in immune regulation, its powerful proinﬂammatory eﬀects
are unequivocal. In the classic lupus model, the MRL/lpr
mice, high TNF-α was found in their serum as well as in
their nephritic kidneys, and both serum and renal TNF-α are
correlated with disease activity [54–56]. Anti-TNF therapy
in MRL/lpr mice is beneﬁcial [57, 58]. In NZB/W mice,
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amounts of TNF-α,a n dl o wd o s a g e so fT N F - α administered
in late NZB/W disease accelerated renal damage [59, 60].
TNF-α can be induced by immune complexes and is
locallyproducedintheimmunecomplexglomerulonephritis
lesions of patients with SLE kidney disease, as it is produced
in the inﬂamed kidneys of lupus mice [61–64].
To determine whether administration of TNF-α would
accelerate renal injury and mortality, D. C. Brennan
et al. injected murine rTNF-α intraperitoneally into female
NZB/WorC3H/FeJmiceattwodoses,2.0microgramsor0.2
micrograms, three times weekly for 2 or 4 months beginning
at 2 or 4 months of age. Administration of the lower dose
of rTNF-α accelerated renal disease and mortality rate when
treatment was initiated at 4 months of age. At the higher
dose, rTNF-α promoted disease. Treatment administered
from 2–4 months of age did not accelerate renal disease [28].
Overall the data presented above indicate that on the one
hand, early TNF-α is required to suppress autoimmunity but
on the other hand, its presence may aid the development of
renal pathology [20].
T.Takemura et al. have found that TNF-α is clearly
expressed in glomeruli of LN patients, mainly by inﬁltrat-
ing macrophages but also by endothelial cells, glomerular
visceral epithelium, and mesangial cells (MCs) of all eight
samples with WHO class III and IV LN, while no TNF-
α is detected in healthy kidney tissues [61]. TNF-α is also
found in the interstitium. R. Herrera-Esparza et al. have
analyzed 19 kidney biopsies with class III or IV LN and
demonstrated TNF-α expression in 10 of these biopsies [62].
TNF-α was seen along the interstitial space of the glomerular
loops and in tubular epithelium. TNF-α mRNA was detected
in six biopsies and seen in tubular epithelium and in
mononuclear cells inﬁltrating the glomerular loops [62]. It
is interesting that TNF-α was mostly found in samples with
high histological activity indices. M.Aringer and J.S. Smolen
showed that glomerular TNF-α expression was correlated
with histological activity but was largely independent of the
WHO class [19]. The involvement of TNF-α in LN is further
supported by the improvement of LN under TNF-α blocking
therapy (e.g., inﬂiximab) [63, 64]. All these studies indicate
that TNF-α is expressed in LN of all WHO classes and
high TNF-α expression is associated with high histological
disease activity. In our previous study, we found markedly
up-regulated renal expression of TNF-α in class III and
class IV LN by immunohistochemical studies, and the up-
regulation of TNF-α was correlated with increased number
of proliferating cell nuclear antigen (PCNA-)positive cells,
CD68-positive cells and the activity index of renal pathologic
changes [65].
The up-regulated renal TNF-α expression is considered
to play an important role in the activation of local inﬂamma-
tion and formation of tissue damage. TNF-α is at the top of
inﬂammation cascade, and the activation of TNF-α signaling
pathwaycouldtransmitinﬂammatorysignalingbyactivation
of NF-κB, which enters the nucleus and activates transcrip-
tion of proinﬂammatory gene targets such as interleukin-
1β (IL-1β), IL-6, and IL-8 [66]. In inﬂamed kidneys of
SLE, TNF-α is induced by IC and promotes inﬂammation
and secondary tissue destruction; liberation of autoantigens
during necrosis could fuel autoimmunity [19]. The ﬁndings
from our previous study are consistent with previous reports
where TNF-α is found to be highly expressed in glomeruli in
all forms of LN [62, 67], and the degree of TNF-α expression
correlates with renal inﬂammatory activity, as measured by
a histological activity index. In our previous immunohis-
tochemical study, we also found that the renal expression
of TNF-α, TRADD, RIP, and TRAF-2 was markedly up-
regulated in class III and class IV LN, these results suggested
that the proinﬂammatory eﬀect mediated by TNF-α signal-
ing was facilitated in local tissue [65]. Our study showed
the number of PCNA-positive cells increased markedly in
glomerular endothelial cells, glomerular mesangial cells, and
parietal epithelial cells lining Bowman’s capsule, endothelial
cells in renal interstitial capillaries and larger vessels, and
tubular epithelium in specimens from patients with class III
and IV LN as well. This suggested that there is considerable
cell proliferation in these tissues. The increase in the number
of PCNA-positive cells was consistent with the up-regulation
of TNF-α, TRADD, RIP, and TRAF-2, suggesting that the
TNF-α–TRADD–RIP–TRAF-2 signaling could mediate cell
proliferation in LN. We also found that CD68-positive
macrophages were markedly increased in class III and IV LN,
and the up-regulation of TNF-α, TRADD, RIP, and TRAF-
2 correlated with increased number of CD68-positive cells
and the activity index of renal pathologic changes. CD68
plays a critical role of macrophage maturation and thus its
increase would facilitate the enhancement of macrophage-
mediated immune responses such as TNF-α release. The
WHO classiﬁcation of LN (class I-VI) does not equally
distribute disease activity. For example, when renal sclerosis
occurs in class VI, local inﬂammatory activity may be less
severe under microscope. Our previous study has apparently
demonstrated that the expression of TNF-α and TNF-α
adapter proteins is independent of the WHO class of LN
[65]. By in vitro study we showed knockdown TRAF-2
by siRNA signiﬁcantly suppressed soluble aggregated IgG
(AIgG)-induced up-regulation of TRAF-2, IL-1β, and IL-6.
Meanwhilethecellproliferationwasinhibited,andapoptotic
cells were increased. From these results we concluded that
TRAF-2 could induce the proinﬂammatory and proliferative
eﬀects of soluble AIgG on rat MCs. Thus, TRAF-2 may
represent a future target for therapy of IC-mediated GN
[68].
Our previous study has showed that the expression of
mRNA for TNF-α adapter molecules, such as TRADD, RIP-
1, and TRAF-2, decreased signiﬁcantly in PBMCs from
patients with SLE, and the expression of these adapters
was negatively correlated with the SLE activity index [46];
but the expression of TNF-α, TRADD, RIP, and TRAF-2
in glomerular and tubular cells was increased in Class III
and IV LN while the increased TNF-α,T R A D D ,R I P ,a n d
TRAF-2 levels also correlated with the number of CD68-
positive or PCNA-positive cells and renal pathologic severity
[65]. The reason for the remarkable discrepancy in the
expression of TNF-α adapter proteins, TRADD, RIP, and
TRAF-2 in various organic tissues is unknown but may be
related to distinct role and regulating factors of TNF-α and
its adapter proteins in diﬀerent tissues [65]. This discrepancyJournal of Biomedicine and Biotechnology 5
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Figure 1: Distinct role and regulating factors of TNF-α and its adapter proteins immune system and organic tissues. TNF-α blocking in
diﬀerent tissues may lead to diﬀerent consequences.
may indicate that TNF-α blocking in distinct tissue could
lead to diﬀerent consequences (Figure 1).
4. ClinicTrialsof TNF-α Blockade in SLE
SLE is an autoimmune disease with inﬂammatory tissue
damage and TNF-α participates in SLE pathogenesis. As
“TNF is at the top of a pro-inﬂammatory “cascade”...block-
ing just this one of the many pro-inﬂammatory cytokines
might,bymeansofitsdownstreameﬀects,haveanimportant
inﬂuence on the complex disease process...”[ 69], blocking
TNF-α in SLE might be beneﬁcial to SLE patients. There are
severalclinictrialsaboutTNF-αblockinginSLEbynow,and
the results seem to be not so exciting [6, 70–72].
M.Aringer et al. reported an Open-Label Study in 2004
about the safety and eﬃcacy of TNF-Blockade in SLE [6].
6 patients with moderately active SLE (4 with nephritis and
3 with arthritis refractory to other therapies) were given 4
infusions of 300mg doses of inﬂiximab, a chimeric anti-
TNF-α antibody, in addition to immunosuppression with
azathioprine or methotrexate. The only signiﬁcant adverse
events observed were urinary tract infection in 3 patients, 1
of which was accompanied by Escherichia coli bacteremia,
and a prolonged febrile episode of putatively viral origin in 1
of them. These patients had similar infectious conditions in
thepast.Noneofthepatientsneedterminatingthetreatment
prematurely. Levels of antibodies to ds-DNA and cardiolipin
increased in 4 patients, but this was not associated with a
decrease in serum complement levels, with vascular events
or with ﬂares. In contrast, disease activity declined during
therapy. All 3 patients with joint involvement experienced
remission of arthritis, which relapsed 8–11 weeks after
the last inﬂiximab infusion. In the 4 patients with lupus
nephritis, proteinuria decreased signiﬁcantly within 1 week
after initiation of therapy and was diminished by >60%
within 8 weeks, remaining at low levels until the end of
the observation period (at least several months). From these
exciting results they concluded that Inﬂiximab did not lead
to adverse events related to increase of SLE activity although
autoantibodies to ds-DNA and cardiolipin increased [6].
In 2008, M.Aringer and J.S. Smolen published another
paper about the changes in autoantibodies occurring in
SLE patients treated with 4 infusions of the chimeric anti-
TNF-α antibody inﬂiximab [70]. In the open-label safety
study, 7 patients with SLE were treated with inﬂiximab at
weeks 0, 2, 6, and 10 in combination with azathioprine
or methotrexate. Autoantibodies to ds-DNA increased in 5
of 7 patients. Histone, chromatin, and IgM anti-cardiolipin
levels were increased in 4 of 7, 6 of 7, and 4 of 7 patients,
respectively, peaking 4–10 weeks after the last inﬂiximab
infusion, but falling to baseline levels or lower thereafter. In
the in vitro experiments, TNF-α withdrawal after long-term
incubation with recombinant human TNF-α led to increased
percentages of apoptotic cells. These results suggested that
while TNF-α blockade was clinically eﬀective, the majority
of SLE patients treated with inﬂiximab showed an increase in
autoantibodies to nuclear antigens and phospholipids. These
increases were transient and were not associated with disease
ﬂares. These results indicated that increased availability of
apoptotic antigens after TNF-α b l o c k a d em a yp l a yar o l e
in the autoantibody formation induced by TNF-α blockade
[70].
In 2009, Uppal et al. reported a pilot study for the
eﬃcacy and safety of inﬂiximab in active SLE [71]. A total
of 46 individuals (27 patients with active SLE and 19 healthy
control volunteers) were studied. Nine patients with SLE6 Journal of Biomedicine and Biotechnology
were allocated to treatment arm and 18 were allocated to
control arm. In addition to conventional treatment, treat-
ment arm received inﬂiximab infusions 3mg/kg body weight
at0,2,and6w eeksandthenq8w eeksforat otalof24w eeks,
that is, a total of ﬁve doses. Four patients from treatment
arm dropped out due to inﬂiximab infusion reaction and 12
patients dropped out from the control arm. The treatment
group showed signiﬁcantly greater improvement in SLE
Disease Activity Index (SLEDAI). Improvements in several
Health status (SF-36) subscales, patient global assessment
(PGA) of disease activity and Visual Analogue Scale-(VAS-)
Fatigue, were also greater in the treatment group but did not
achieve statistical signiﬁcance. The mean levels of TNF-α,
soluble TNFR-1 (p55 srTNF-α), and TNFR-2 (p75 srTNF-
α) were higher in the SLE group compared with the healthy
controls but did not change signiﬁcantly over the study
period. No safety issues with inﬂiximab were seen in this
study.InviewofimprovementinseveralSLEparametersand
good safety proﬁle of inﬂiximab, they thought anti-TNF-α
therapy was an interesting candidate approach for treating
SLE [71].
Recently Aringer M. et al. reported a long-term follow-
up study of 13 patients about the adverse events and eﬃcacy
of TNF-α blockade with inﬂiximab in SLE patients [72].
Out of nine patients with LN, six had a long-term response
after four infusions of inﬂiximab in combination with
azathioprine, lasting for up to 5 years. All ﬁve patients with
lupus arthritis responded, but this response did not last for
>2 months after the last infusion. One additional patient had
a long-lasting improvement in SLE interstitial lung disease.
No symptoms suggestive of inﬂiximab-induced SLE ﬂares
occurred in any patients. Short-term treatment appeared rel-
atively safe, but one patient developed deep-vein thrombosis
andseveralinfections.Underlong-termtherapy,twopatients
had life-threatening or fatal events, namely, central nervous
system lymphoma and Legionella pneumonia. Retreatment
andtreatmentwithoutconcomitantimmunosuppressionled
to drug reactions. Their study indicated that short-term
therapy with four infusions of inﬂiximab in combination
with azathioprine was relatively safe and had remarkable
long-term eﬃcacy for LN and, potentially, also interstitial
lung disease. Long-term therapy with inﬂiximab, however,
was associated with severe adverse events in two out of three
SLE patients, which may have been provoked by inﬂiximab
and/or by their long-standing refractory SLE and previous
therapies [72].
Recently E. Soforo et al. have reported 6 women
who developed active SLE satisfying American College
of Rheumatology diagnostic criteria with life-threatening
manifestations after receiving TNF blockade for treatment
of rheumatoid arthritis or psoriatic arthritis [73]. They
thought the mechanism of TNF blocker-induced lupus may
be related to a shift from death by apoptosis to necrosis, the
latter resulting in the release of nuclear debris, a trigger of
ANA production and lupus. They concluded that patients
treated with TNF blockers, especially those with positive
ANA, should be closely monitored for development of SLE
[73]. These data indicated that induction of ANA or pre-
existing high-titer ANA in TNF-treated patients is associated
with the development of lupus and therefore TNF blockade
is ill-advised in this group of patients.
In summary, TNF-α exerts both deleterious tissue-
damaging eﬀects mainly through its pro-inﬂammatory
activities and beneﬁcial activities by dampening aggressive
autoimmune responses. SLE is a disease with autoimmune
disturbance and inﬂammatory damage, so blocking TNF-
α in this autoimmune-prone chronic inﬂammatory disease
may lead to diﬀerent outcomes, depending on timing and
duration of treatment.
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